

INDUSTRY PAYMENTS ANALYTICS



Payments Insights & Trends for **Amgen**


www.aissel.com/konectar/oncology



Industry Overview

Life Sciences companies need to track HCP Payments to get an understanding of average spends on HCPs, competitor affiliations and overall HCP utilization for different engagements. This can provide valuable insights to plan strategic KOL initiatives and engagements. Payments Analytics uses Open Payments data and creates insightful reports around the industry-HCP engagements.


An overview of the top 20 Oncology companies and their spend (2013-2017)




Sunshine Act and its Significance for Life Sciences Companies

The Physician Payments Sunshine Act (PPSA) requires medical product manufacturers to disclose to the Centers for Medicare and Medicaid Services (CMS) any payments or other transfers of value made to physicians or teaching hospitals. It also requires certain manufacturers and group purchasing organizations (GPOs) to disclose any physician ownership or investment interests held in those companies.

Life Sciences companies payments trends (2013-2017)



In 2017, Life Sciences companies spent \$8.40 billion on 628,000 HCPs.




25% (\$2 Billion) of the overall Payments was made to 7.6% (44,390) Oncology experts in 2017.




Amgen Industry Payments Trends

Amgen is a biopharmaceutical company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas that include Bone Health, Cardiovascular, Hematology /Oncology, Inflammation and Neuroscience. Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.


Amgen - HCP Engagements Payments Trends (2017)



Amgen spent \$7,144,971 on 10,850 Oncology experts (General Payments).




Amgen has spent \$3.2mn on Speaking Fee and \$1.6mn as Consuting Fee on Oncology experts in 2017.



In 2017, Amgen significantly increased Associate Research Payments on Oncology experts, with 88 new studies initiated in the Oncology space.





Geo Location & Network of Top 20 Oncology Experts Engaged by Amgen 2017



Professional Network and Geo locations of Top 20 Oncology experts engaged by Amgen (General Payments 2017). The network is based on co-authorship, research activities, speaking engagements and organizations of Oncology Experts.

Amgen - Oncology Experts' Experience and Engagement by Payment Types







Amgen - Payments across Engagement Types (2017)



Total Oncology experts engaged by Amgen for Speaking, Consulting and Research (2017)

Speaking - 263
Consulting - 240
Research - 33

Top 5 Oncology conditions treated by experts engaged by Amgen (2017)

Solution

Breast Neoplasms
Prostatic Neoplasms
Solution
Skin Neoplasms
Ovarian Neoplasms
Endometrial Neoplasms




Competitor View of HCP Engagement


Top 20 Oncology experts engaged by Amgen and their competitors (General Payments 2017)

No.	HCP Name			Companies			
1	Dr. Robert Gabriel Feldman (California)	Amgen \$108,354	Merck \$28,893	Janssen \$24,195	Lilly USA \$4,508	Roche \$1,672	
2	Dr. Jonathan Zager (Florida)	Amgen \$107,642	Novadaq \$245	Allergan \$208	Merck \$102		
3	Dr. Leroy Wayne Keiser (California)	Amgen \$106,355	Teva \$47,690	Taiho Oncology \$8,903	Lilly USA \$2,057	AstraZeneca \$111	
4	Dr. Daniel G Haller (Pennsylvania)	Amgen \$105,545	Taiho Oncology \$73,539	Genentech \$22,986	Lilly USA \$19,054	Merck \$8,845	
5	Dr. Fadi S Braiteh (Nevada)	Amgen \$94,809	E.R. Squibb & Sons \$137,171	AstraZeneca \$106,432	Insys Therapeutics \$91,657	Genentech \$63,179	
6	Dr. Paul Leslie Weinstein (Connecticut)	Amgen \$93,360	Lilly USA \$46,814	Boehringer Ingelheim \$10,231	Celgene \$7,893	AstraZeneca \$5,708	
7	Dr. Ralph V Boccia (Maryland)	Amgen \$86,057	Heron Therapeutics \$268,443	E.R. Squibb & Sons \$83,097	Daiichi Sankyo \$55,038	Celgene \$43,773	
8	Dr. James Richard Berenson (California)	Amgen \$85,803	E.R. Squibb & Sons \$157,342	Janssen \$98,765	Millennium Pharma \$45,995	Celgene \$38,641	
9	Dr. Joseph M Tuscano (California)	Amgen \$85,782	Celgene \$65,940	Seattle Genetics \$24,556	Gilead Sciences \$4,160	Pharmacyclics \$93	
10	Dr. Noam Z Drazin (California)	Amgen \$83,662	AstraZeneca \$49,023	Lilly USA \$34,041	E.R. Squibb & Sons \$19,084	Seattle Genetics \$4,296	
11	Dr. Dana S Thompson (Tennessee)	Amgen \$83,241	Celgene \$10,270	Gilead Sciences \$5,318	Heron Therapeutics \$4,537	Merck \$106	
12	Dr. Raoul S Concepcion (Tennessee)	Amgen \$82,784	Astellas Pharma \$97,684	Dendreon Pharma \$34,100	Janssen \$6,722	AstraZeneca \$5,363	
13	Dr. Joshua Ryan Richter (New Jersey)	Amgen \$81,954	Millennium Pharma \$46,091	Janssen \$43,017	E.R. Squibb & Sons \$28,933	Celgene \$15,183	
14	Dr. David John Kuter (Massachusetts)	Amgen \$74,378	Shire \$26,587	Incyte Corp \$4,626	Bioverativ Therapeutics \$3,490	Genzyme \$2,172	
15	Dr. David S Siegel (New Jersey)	Amgen \$73,659	Millennium Pharma \$46,529	Celgene \$15,875	Janssen \$5,681	E.R. Squibb & Sons \$2,255	
16	Dr. Matthew Smith (Massachusetts)	Amgen \$69,103	Bayer \$21,116	Janssen \$13,015	Hexal \$6,591	Abbvie \$4,215	
17	Dr. Edward R George (North Carolina)	Amgen \$65,391	Alexion Pharma \$77,178	Merck \$61,465	Celgene \$7,369	Genentech \$324	
18	Dr. Imad A. Tabbara (District of Columbia)	Amgen \$63,688	Millennium Pharma \$77,740	Celgene \$53,349	Genentech \$30,614	Pharmacyclics \$28,105	
19	Dr. William Ira Bensinger (Washington)	Amgen \$62,895	Celgene \$117,683	Millennium Pharma \$43,357	Janssen \$28,218	Jazz Pharma \$17	
20	Dr. Devalingam Mahalingam (Illinois)	Amgen \$58,211	EMD Serono \$54,240	Genentech \$36,647	E.R. Squibb & Sons \$21,334	Bayer \$9,393	



Amgen - Top 5 Oncology Experts (General and Research Payments 2017)





Aissel Technologies specializes in cutting-edge medical Thought Leader solutions. konectar, our KOL Management Platform has the most innovative features built using robust technologies for data analytics and reporting, sophisticated algorithms using machine learning for client-specific KOL identification. With a really cool user interface, users can Discover, Profile and Engage the right medical experts with konectar.

_____ Contact Us _____

Email: sales@aissel.com | Call: +1 347 966 8181 | Web: www.aissel.com/konectar/oncology